Skip to main content
News

Overton’s nomination withdrawal means no clear end for FDA leadership vacuum

Overton’s nomination withdrawal means no clear end for FDA leadership vacuum

Feed excerpt — reported by The Hill

The White House's abrupt withdrawal of Heidi Overton as President Trump's nominee to lead the Food and Drug Administration (FDA) means the agency will remain without stable leadership six months after the former commissioner resigned, leaving industry observers anxious. The Trump administration's last-minute pulling of Overton's nomination caught senators by surprise this week. Sen. Bill Cassidy (R-La.), chair of the Senate Health,…

MAP records observable characteristics of the original article (publisher, author, date, references, framing cues). MAP does not verify the article’s claims or score it. Read the full original story at The Hill →

Original Source

This article was syndicated from The Hill. All rights remain with the original publisher.